SCHEMBL13761632

SCHEMBL13761632

CC(C)(C)c1ccc(-c2cc3ccccc3s2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APP P05067 2/20 0.62
▸ HSD17B1 P14061 1/20 0.55
▸ HSD17B2 P37059 1/20 0.55
▸ CA1 P00915 2/20 0.54
▸ CA9 Q16790 2/20 0.54
▸ CA2 P00918 1/20 0.54
▸ TNF P01375 1/20 0.51
▸ NOD1 Q9Y239 1/20 0.51
▸ ERN1 O75460 3/20 0.50
▸ HDAC2 Q92769 1/20 0.46
▸ ESR1 P03372 4/20 0.44
▸ ESR2 Q92731 4/20 0.44
▸ CA12 O43570 1/20 0.43
▸ NPC1 O15118 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32677328 0.85 APP (0.81) APPHSD17B1HSD17B2CA1CA9
SCHEMBL27159530 0.85 APP (0.81) APPHSD17B1HSD17B2CA1CA9
SCHEMBL26325135 0.82 ESR1 (0.44) APPTNFNOD1ESR1ESR2
SCHEMBL27631114 0.81 HSD17B1 (0.77) APPHSD17B1HSD17B2CA1CA9
SCHEMBL8338272 0.80 APP (0.68) APPHSD17B1HSD17B2CA1CA9
SCHEMBL23555697 0.80 APP (0.72) APPHSD17B1HSD17B2CA1CA9
SCHEMBL5768436 0.80 APP (0.72) APPHSD17B1HSD17B2CA1CA9
SCHEMBL28813263 0.80 APP (0.67) APPHSD17B1HSD17B2CA1CA9
SCHEMBL163523 0.79 APP (0.71) APPHSD17B1HSD17B2CA1CA9
SCHEMBL29766071 0.79 APP (0.71) APPHSD17B1HSD17B2CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557110-B2 MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine TEIJIN PHARMA LIMITED (JP) 2009-07-07 — — US disclosed
Send feedback